18 June 2025 - The US FDA has approved long-acting injectable lenacapavir for HIV prevention. The new medicine is administered by injection once every 6 months and is a significant step in improving prevention options for people at risk of HIV infection around the world. In an interview with the New York Times, Gilead Sciences has announced a US list price of $28,218/person year.

In a research paper published in The Lancet HIV this week, experts found that generic lenacapavir could cost $35-$46/person year. This could fall to $25 per person year for a committed demand of five to ten million people within the first year, bringing pricing in line with or lower than current oral PrEP.

Read UNAIDS press release